Efeitos do consumo de Konjac glucomanano (Konjac Massa mf®) sobre o perfil glicêmico e parâmetros metabólicos de camundongos com diabetes tipo 1 induzido por STZ

Abstract

Type 1 diabetes mellitus (T1DM) is a metabolic condition characterized by immune- mediated destruction of pancreatic beta cells. Therapies aimed at enhancing insulin levels

and sensitivity are essential for individuals with T1DM. Dietary interventions, particularly those involving dietary fibers, have emerged as promising non-pharmacological approaches for glycemic control. Konjac glucomannan (KGM) has shown notable hypoglycemic properties in animal models of T1DM. Thus, this study aimed to evaluate the effects of KGM, in the form of the commercial product Konjac Massa MF®, on the glycemic and lipid profiles of mice with STZ-induced T1DM. Male C57BL/6J mice rendered diabetic with streptozotocin (STZ) were treated with Konjac Massa MF® (120 mg/kg/day intragastric way) for four weeks. During the treatment period, glycemia, weight gain, water and food consumption were monitored. Glucose (IPGTT) and insulin (IPITT) tolerance tests were performed, followed by plasma collection for biochemical analyses. The results demonstrated a significant reduction in fasting glycemia in diabetic mice treated from the third week compared to untreated diabetics (245.20 ± 26.91 vs. 412.10 ± 25.18 mg/dL). However, no significant difference in glucose tolerance was observed between treated and untreated diabetic groups. The treated group exhibited improved insulin sensitivity (209.90 ± 57.20 vs. 378.50 ± 61.97 mg/dL; 60 min: 213.70 ± 48.49 vs. 361.00 ± 61.34 mg/dL; 90 min: 197.90 ± 51.85 vs. 316.30 ± 60.74 mg/dL; 120 min: 234.50 ± 59.23 vs. 318.30 ± 54.78 mg/dL). Treatment also resulted in reduced levels of serum MDA (17.10 ± 1.51 vs. 26.42 ± 1.48 nmol/dL), cholesterol (59.39 ± 8.61 vs. 156.83 ± 32.42 mg/dL), creatinine (1.46 ± 0.14 vs. 2.08 ± 0.23 nmol/dL), and ALT (39.39 ± 6.89 vs. 82.83 ± 25.19 nmol/dL). In conclusion, Konjac Massa MF® shows promise as a therapeutic agent for enhancing insulin sensitivity and hepatic function in T1DM models. Further research is warranted to elucidate the underlying protective mechanisms of KGM and to determine its clinical applicability in managing T1DM and its associated complications.